InterVenn Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022
InterVenn Biosciences, the leader in glycoproteomics, today announced Aldo Carrascoso, the company's CEO and Co-Founder, is scheduled to present at the J.P. Morgan 40th Annual Healthcare Conference on January 12, 2022, from 3:00 ? 3:25 pm EST. Mr. Carrascoso will provide a company overview of InterVenn and its first-of-its-kind glycoproteomics solutions.
Following the company presentation, management will participate in a virtual breakout session. InterVenn management will also participate in one-on-one meetings with investors, analysts, and other interested parties during the conference.
About InterVenn
InterVenn Biosciences has developed a proprietary glycoproteomic biomarker discovery and interrogation platform based on artificial intelligence-empowered mass spectrometry for next-gen precision medicine. The company is working on developing novel predictive tests in a range of indications, including ovarian, pancreatic, liver, prostate, lung, kidney and other cancers, as well as on tests for treatment response prediction and monitoring of treatment efficacy, and disease progression. https://intervenn.com
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly...
The Industrial Technology Research Institute (ITRI) convened the 2024 ITRI Net Zero Day in Taipei, accelerating industry's transition to net-zero emissions. The event highlighted key innovations and successful business cases, focusing on the...
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...
Bristow Group Inc. , the global leader in innovative and sustainable vertical flight solutions, today announced it will release its first quarter 2024 financial results and selected financial outlook for 2025 and 2026 after market close on Tuesday,...
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...
